首页> 外文OA文献 >1768. Efficacy and Safety of Switching From Boosted-Protease Inhibitors (bPI) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Regimens to the Once Daily (QD), Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-Infected Adults: Week 96 Results of the Phase 3, Randomized, Non-Inferiority EMERALD Trial

【2h】

1768. Efficacy and Safety of Switching From Boosted-Protease Inhibitors (bPI) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Regimens to the Once Daily (QD), Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-Infected Adults: Week 96 Results of the Phase 3, Randomized, Non-Inferiority EMERALD Trial

机译：1768.从增强蛋白酶抑制剂（BPI）加上Emtricisabine / Tenofovir Disoprocate（F / TDF）方案的疗效和安全性转换为曾经每日（QD），单级片剂/ Cobicistat / Emtricicabine / Tenofovir的单片植物（str）在病毒学抑制的阿拉芬酰胺（D / C / F / TAF），HIV-1感染的成人：第3周的96个结果3阶段，随机，非劣势祖母绿试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Joseph Eron; Chloe Orkin; Douglas Cunningham; Federcio Pulido; Frank Post; Stéphane De Wit; Erkki Lathouwers; Veerle Hufkens; Romana Petrovic; Erika Van Landuyt;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 [J] . Eron Joseph J., Orkin Chloe, Cunningham Douglas, Antiviral Research . 2019,第期

机译：第9周的疗效和安全结果3阶段，随机祖母绿试验评估从增强蛋白酶抑制剂的切换加上Emtricitabine / Tenofovir Disoproxil富马酸莫霉素治疗达伦韦/钴/ Emtricitabine / Tenofovir Alafenaine的单片体方案（D / C / F / TAF）在治疗经验丰富的病毒学 - 被抑制的成年人与HIV-1一起生活
2. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial [J] . Post Frank A., Yazdanpanah Yazdan, Schembri Gabriel, HIV clinical trials . 2017,第3期

机译：Emtricicabine / Tenofovir Alafenaine（FTC / TAF）与Emtrickabine / Tenofovir Disoproxil umarate（FTC / TDF）作为用于治疗病毒学抑制成人的HIV-1感染的骨干的疗效和安全性：由随机的第三代理分析亚组分析 -blind，主动控制的第3阶段试验
3. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials [J] . Lathouwers Erkki, Wong Eric Y., Brown Kimberley, AIDS Research and Human Retroviruses . 2020,第1期

机译：每日48周的抗性分析曾经，单片机中达伦韦/诺福尼亚州/替斯塔布胺/替诺维尔（D / C / F / TAF）与HIV-1的成人中，III期随机琥珀和祖母绿试验
4. 1768. Efficacy and Safety of Switching From Boosted-Protease Inhibitors (bPI) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Regimens to the Once Daily (QD) Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed HIV-1-Infected Adults: Week 96 Results of the Phase 3 Randomized Non-Inferiority EMERALD Trial [O] . Joseph Eron, Chloe Orkin, Douglas Cunningham, -1

机译：1768.从强化蛋白酶抑制剂（bPI）加上恩曲他滨/替诺福韦富马酸二氯吡呋酯（F / TDF）方案改为每日一次（QD）单药方案（STR）Darunavir / Cobicistat / Emtricitabine / Tenofovir的功效和安全性在病毒学上被抑制HIV-1感染的成年人中Alafenamide（D / C / F / TAF）：第3周随机非自卑性EMERALD试验的第96周结果
5. Week 48 Results of EMERALD: A Phase 3, Randomized, Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD), Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-infected Adults [O] . Chloe Orkin, Jean-Michel Molina, Joel Gallant, 2017

机译：每周48个祖母绿的结果：第3期，随机的非劣升性研究，评估从增强蛋白酶抑制剂（BPI）加上的促蛋白（BPI）和替尼罗韦（FTC）/ Tenofovir Disoproxil umarate（TDF）方案的疗效和安全性对一次每日（QD ），在病毒学抑制的单片机/ Cobicistat / Emtricisabine / enftricitabine / Tenofovir Alafenainide（D / C / F / TAF）的单片植物（str），HIV-1感染的成年人

著录项

引文网络

相似文献

相关主题

期刊订阅